The dysregulation of ANRIL has also been reported in a range of cancers including pancreatic cancer(Wang et al. 2022a, b), cervical cancer(Zhao et al. 2018), breast cancer(Xu et al. 2017; Ma et al. 2022), gastric cancer(Kangarlouei et al. 2019) and multiple myeloma(Wang et al. 2020). This evidence concerns the gene CDKN2B-AS1 and breast carcinoma.